<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The increase in the therapeutic arsenal in the last 20 years, has given rise to changes in treating <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) with only <z:chebi fb="0" ids="39447">pyrimidines</z:chebi> to combine several cytotoxic drugs </plain></SENT>
<SENT sid="1" pm="."><plain>However, the present question is to determine the optimal sequence of this combination </plain></SENT>
<SENT sid="2" pm="."><plain>This review presents an update of data on chemical and clinical features of chemotherapy used for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> and the mechanisms of cellular resistance and potential predictive and prognostic biomarkers, which may contribute to a better selection of a therapeutic strategy </plain></SENT>
</text></document>